StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT - Free Report) in a research report report published on Wednesday morning. The firm issued a sell rating on the biotechnology company's stock.
Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They set a "buy" rating and a $35.00 target price for the company.
Check Out Our Latest Stock Analysis on VTVT
vTv Therapeutics Price Performance
VTVT stock traded down $0.03 during mid-day trading on Wednesday, reaching $17.87. 6,394 shares of the company's stock were exchanged, compared to its average volume of 7,425. vTv Therapeutics has a 12-month low of $8.10 and a 12-month high of $30.99. The stock's 50 day moving average is $14.89 and its 200 day moving average is $14.81. The company has a market cap of $57.01 million, a price-to-earnings ratio of -3.94 and a beta of 0.73.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter.
Institutional Trading of vTv Therapeutics
A hedge fund recently bought a new stake in vTv Therapeutics stock. FMR LLC bought a new position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 178,200 shares of the biotechnology company's stock, valued at approximately $2,402,000. FMR LLC owned about 5.92% of vTv Therapeutics as of its most recent SEC filing. 17.51% of the stock is currently owned by institutional investors.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
See Also
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
